AskBio owns and operates a cell line manufacturing process and an extensive capsid library and has generated hundreds of proprietary third generation gene vectors. AskBio’s double strand adeno-associated virus vectors (AAV) have low effective dose, more cell type specificity and less potential systemic effects. AskBio’s proprietary production line requires less resources and regulatory steps and has been used in seven clinical-grade productions, over 50 preclinical lots and over 4,000 grade lots.